Date:9/12/2011

xed price nature of contracts or the loss or delay of large studies, risks associated with acquisitions and investments, the Company's ability to increase order volume, the pace of translation of orders into revenue in late-stage development services, testing mix and geographic mix of kit receipts in central laboratories, fluctuations in currency exchange rates, and other factors described in the Company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no duty to update any forward looking statement to conform the statement to actual results or changes in the Company's expectations.

'/>"/>

SOURCE Covance Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2
Related medicine technology :

1. Covance Reports Second Quarter Revenue of $518 Million, GAAP EPS of $0.61, and Pro Forma EPS of $0.66
2. Covance to Present at Bairds 2011 Growth Stock Conference
3. Covance Inc. Invites You to Join the Webcast of Its First Quarter 2011 Financial Results Conference Call
4. Covance to Present at the 2nd Annual Morningstar/NYSSA Healthcare Conference
5. Takeda Enters Into Global Strategic Partnerships With Covance and Quintiles
6. Covance Reports Fourth Quarter Revenue of $492 Million, GAAP EPS of $0.45, and Pro Forma EPS of $0.56
7. Covance Reports Third Quarter Financial Results and Takes Actions to Strengthen Future Performance
8. Covance and sanofi-aventis Finalize Agreements for 10-year Strategic R&D Alliance
9. Covance and Sanofi-Aventis Sign Definitive Agreements for 10-Year Strategic R&D Alliance
10. Covance Board Authorizes $250 Million Stock Buyback
11. Covance to Present at Morgan Stanley Global Healthcare Conference